HRP20020652A2 - Use of il-18 inhibitors - Google Patents

Use of il-18 inhibitors Download PDF

Info

Publication number
HRP20020652A2
HRP20020652A2 HRP20020652A HRP20020652A2 HR P20020652 A2 HRP20020652 A2 HR P20020652A2 HR P20020652 A HRP20020652 A HR P20020652A HR P20020652 A2 HRP20020652 A2 HR P20020652A2
Authority
HR
Croatia
Prior art keywords
inhibitor
use according
disease
production
treatment
Prior art date
Application number
Other languages
English (en)
Croatian (hr)
Inventor
Yolande Chvatchko
Charles Dinarello
Christine Plater-Zyberk
Santer Van Deventer
Menachem Rubinstein
Daniela Novick
Soo-Hyun Kim
Original Assignee
Applied Research Systems
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems, Yeda Res & Dev filed Critical Applied Research Systems
Publication of HRP20020652A2 publication Critical patent/HRP20020652A2/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Addiction (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HRP20020652 2000-02-21 2001-02-20 Use of il-18 inhibitors HRP20020652A2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP00103597 2000-02-21
EP00103590 2000-02-21
EP00121651 2000-10-04
EP00125633 2000-11-23
PCT/EP2001/001867 WO2001062285A1 (en) 2000-02-21 2001-02-20 Use of il-18 inhibitors

Publications (1)

Publication Number Publication Date
HRP20020652A2 true HRP20020652A2 (en) 2004-12-31

Family

ID=27439934

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20020652 HRP20020652A2 (en) 2000-02-21 2001-02-20 Use of il-18 inhibitors

Country Status (30)

Country Link
US (1) US20030157094A1 (cs)
EP (1) EP1257292B1 (cs)
JP (1) JP4744763B2 (cs)
KR (3) KR20020086540A (cs)
CN (1) CN1322897C (cs)
AT (1) ATE506959T1 (cs)
AU (2) AU4063601A (cs)
BG (1) BG66134B1 (cs)
BR (1) BR0108514A (cs)
CA (2) CA2683009C (cs)
CY (1) CY1111687T1 (cs)
CZ (1) CZ304485B6 (cs)
DE (1) DE60144514D1 (cs)
DK (1) DK1257292T3 (cs)
EA (1) EA005583B1 (cs)
EE (1) EE05423B1 (cs)
HR (1) HRP20020652A2 (cs)
HU (1) HU227752B1 (cs)
IL (2) IL151388A0 (cs)
ME (1) ME00546B (cs)
MX (1) MXPA02008079A (cs)
NO (1) NO331971B1 (cs)
NZ (3) NZ535299A (cs)
PL (1) PL206549B1 (cs)
PT (1) PT1257292E (cs)
RS (1) RS51737B (cs)
SI (1) SI1257292T1 (cs)
SK (1) SK288032B6 (cs)
TR (2) TR200502508T2 (cs)
WO (1) WO2001062285A1 (cs)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2399148A1 (en) * 2000-02-10 2001-08-16 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
ME00546B (me) * 2000-02-21 2011-10-10 Serono Lab Korišćenje inhibitora il-18
JP2004528010A (ja) 2000-10-11 2004-09-16 バイロン・セラピューティックス・インコーポレーテッド 免疫モジュレーションのための核酸およびポリペプチド
US7718368B2 (en) 2000-12-04 2010-05-18 Viron Therapeutics Inc. Immunomodulatory protein and useful embodiments thereof
EP1425028B1 (en) * 2001-05-16 2009-12-16 Yeda Research And Development Co. Ltd. Use of il-18 inhibitors for the treatement or prevention of sepsis
EP1487457A1 (en) * 2001-11-30 2004-12-22 Pfizer Products Inc. Combination of an il-1/18 inhibitor with a tnf inhibitor for the treatment of inflammation
CA2513584A1 (en) * 2003-01-20 2004-08-05 Vib Vzw The use of yop proteins or rho gtpase inhibitors as caspase-1 inhibitors
CA2523912A1 (en) * 2003-04-30 2004-11-11 Japan Science And Technology Agency Human antihuman interleukin-18 antibody, fragment thereof and method of using the same
CA2545733A1 (en) * 2003-11-10 2005-05-26 Vertex Pharmaceuticals Incorporated Methods for monitoring il-18
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
EP2177907B1 (en) 2004-06-30 2014-01-01 Atsuo Sekiyama Indicator agent for noninflammatory stress response and use therefor
AU2005264453B2 (en) 2004-07-16 2011-07-14 Atsuo Sekiyama IL-18 receptor antagonist and pharmaceutical composition containing the antagonist
AU2006254103B2 (en) 2005-06-03 2012-09-06 Ares Trading S.A. Production of recombinant IL-18 binding protein
AU2006256763B2 (en) 2005-06-10 2012-08-02 Ares Trading S.A. Process for the purification of IL-18 binding protein
EP1746167A1 (en) * 2005-07-20 2007-01-24 Apoxis SA Method for the identification of compounds susceptible to inhibit inflammation
TWI422387B (zh) 2006-05-25 2014-01-11 Glaxo Group Ltd 免疫球蛋白
US8440195B2 (en) * 2010-11-12 2013-05-14 National University Corporation Chiba University Inhibition of CD69 for treatment of inflammatory conditions
GB201213968D0 (en) * 2012-08-06 2012-09-19 Isis Innovation Prevention and treatment of osteoarthritis
UA125204C2 (uk) * 2013-09-05 2022-02-02 Аб2 Біо Са Застосування il-18-зв'язувального білка (il-18bp) при запальних захворюваннях
US10882905B2 (en) * 2015-03-05 2021-01-05 Ab2 Bio Sa IL-18 binding protein (IL-18BP) and antibodies in inflammatory diseases
CN106109497A (zh) * 2016-07-25 2016-11-16 深圳爱生再生医学科技有限公司 治疗肝硬化的干细胞制剂
CN106834449B (zh) * 2017-01-10 2019-04-30 东南大学 与原发性胆汁性胆管炎关联的白细胞介素21受体及其应用
JP2021527107A (ja) * 2018-06-14 2021-10-11 ユニベルシテ ドゥ ボルドー インターロイキン−１の阻害薬を使用した胎盤性慢性組織球性絨毛間腔炎の治療
WO2023286694A1 (ja) 2021-07-13 2023-01-19 国立大学法人東海国立大学機構 炎症性腸疾患を治療するための医薬組成物
CN117647645B (zh) * 2024-01-29 2024-04-12 中国人民解放军总医院第一医学中心 Lbp、atf6、m-csfr联用在制备诊断自身免疫性肝病产品中的应用及试剂盒
WO2025229563A1 (en) * 2024-05-03 2025-11-06 Glaxosmithkline Intellectual Property Development Limited Methods of treating inflammatory bowel disease

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985863A (en) * 1996-09-12 1999-11-16 Vertex Pharmaceuticals, Inc. Compositions and methods for decreasing IGIF and IFN-γ production by administering an ICE inhibitor
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5744451A (en) * 1995-09-12 1998-04-28 Warner-Lambert Company N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity
ATE256476T1 (de) * 1996-11-15 2004-01-15 Kennedy Inst Of Rheumatology Unterdrückung von tnfalpha und il-12 in der therapie
US7141393B2 (en) * 1996-12-26 2006-11-28 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18-receptor proteins
US6087116A (en) * 1997-03-12 2000-07-11 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18 (IL-18) receptor polypeptides and their uses
JP4026923B2 (ja) * 1997-03-12 2007-12-26 株式会社林原生物化学研究所 ポリペプチド
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
CA2276216A1 (en) * 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
KR100537558B1 (ko) * 1998-09-01 2005-12-19 가부시끼가이샤 하야시바라 세이부쓰 가가꾸 겐꾸조 인터류킨-18 결합 단백질
AR022952A1 (es) * 1999-03-19 2002-09-04 Smithkline Beecham Corp ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL
CA2399148A1 (en) * 2000-02-10 2001-08-16 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
ME00546B (me) * 2000-02-21 2011-10-10 Serono Lab Korišćenje inhibitora il-18
WO2002032374A2 (en) * 2000-10-18 2002-04-25 Immunex Corporation Methods for treating il-18 mediated disorders

Also Published As

Publication number Publication date
ATE506959T1 (de) 2011-05-15
US20030157094A1 (en) 2003-08-21
IL151388A (en) 2009-09-01
JP4744763B2 (ja) 2011-08-10
CN1404400A (zh) 2003-03-19
CZ304485B6 (cs) 2014-05-28
EE200200463A (et) 2003-12-15
WO2001062285A1 (en) 2001-08-30
NZ520122A (en) 2005-04-29
EP1257292A1 (en) 2002-11-20
NZ535299A (en) 2006-06-30
HU227752B1 (en) 2012-02-28
DE60144514D1 (de) 2011-06-09
AU2001240636B8 (en) 2005-11-03
IL151388A0 (en) 2003-04-10
SI1257292T1 (sl) 2011-08-31
CY1111687T1 (el) 2015-10-07
BG66134B1 (bg) 2011-06-30
CA2399298C (en) 2014-04-15
MXPA02008079A (es) 2003-02-27
CA2399298A1 (en) 2001-08-30
PT1257292E (pt) 2011-07-05
NO331971B1 (no) 2012-05-14
EE05423B1 (et) 2011-06-15
EP1257292B1 (en) 2011-04-27
EA005583B1 (ru) 2005-04-28
KR20020086540A (ko) 2002-11-18
RS51737B (sr) 2011-10-31
TR200202030T2 (tr) 2003-01-21
CZ20022843A3 (cs) 2003-02-12
NZ546294A (en) 2008-02-29
BR0108514A (pt) 2002-12-17
YU60402A (sh) 2005-09-19
PL206549B1 (pl) 2010-08-31
TR200502508T2 (tr) 2007-04-24
DK1257292T3 (da) 2011-07-18
NO20023962L (no) 2002-08-20
CA2683009C (en) 2014-09-23
CA2683009A1 (en) 2001-08-30
HUP0300061A2 (hu) 2003-04-28
HK1051965A1 (en) 2003-08-29
EA200200890A1 (ru) 2003-02-27
KR20070087256A (ko) 2007-08-27
HUP0300061A3 (en) 2005-09-28
SK12082002A3 (sk) 2003-05-02
ME00546B (me) 2011-10-10
JP2003523403A (ja) 2003-08-05
AU4063601A (en) 2001-09-03
NO20023962D0 (no) 2002-08-20
SK288032B6 (sk) 2012-12-03
BG107018A (bg) 2003-09-30
CN1322897C (zh) 2007-06-27
AU2001240636B2 (en) 2005-10-13
KR20070057282A (ko) 2007-06-04
PL357554A1 (en) 2004-07-26

Similar Documents

Publication Publication Date Title
AU2001240636B2 (en) Use of il-18 inhibitors
AU2001240636A1 (en) Use of IL-18 inhibitors
EP1425028B1 (en) Use of il-18 inhibitors for the treatement or prevention of sepsis
US7696154B2 (en) Methods for treating interleukin-18 mediated disorders with interleukin-18 binding proteins
US20100254941A1 (en) Interleukin-18 binding proteins, their preparation and use for the treatment of sepsis
US20090074710A1 (en) Method of treatment using a cytokine able to bind il-18bp to inhibit the activity of a second cytokine
RS60402B1 (sr) Dodaci ishrani
ES2365600T3 (es) Uso de inhibidores de il-18.
HK1051965B (en) Use of il-18 inhibitors

Legal Events

Date Code Title Description
ODRP Renewal fee for the maintenance of a patent

Payment date: 20040114

Year of fee payment: 4

A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
PPPP Transfer of rights

Owner name: MERCK SERONO SA, CH

ODBI Application refused